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Fate mapping of the mouse midbrain–hindbrain constriction
using a site-specific recombination system 
Dawn L. Zinyk*†, Eric H. Mercer‡, Esther Harris§, David J. Anderson‡
and Alexandra L. Joyner§
The mouse midbrain–hindbrain constriction is centrally
involved in patterning of the midbrain and anterior
hindbrain (cerebellum), as revealed by recent genetic
studies using mice and embryological studies in chick
(reviewed in [1,2]). This region can act as an organizer
region to induce midbrain and cerebellar development.
Genes such as Engrailed-1, Pax-2 and Pax-5, which are
expressed in the embryonic cells that will form the
midbrain and the cerebellum, are required for
development of these regions. Fate-mapping
experiments at early somite stages in chick have
revealed that the cerebellar primordium is located both
anterior and posterior to the midbrain–hindbrain
constriction, whereas midbrain precursors lie more
anteriorly. Fate mapping in mice has been complicated
by the inaccessibility of the postimplantation embryo.
Here, we report the use of a new in vivo approach
involving the Cre–loxP site-specific recombination
system [3] to map the fate of cells in the mouse
midbrain–hindbrain constriction. We show that cells
originating in the mouse dorsal midbrain–hindbrain
constriction during embryonic days 9–12 contribute
significantly to the medial cerebellum and colliculi. Our
data demonstrate the feasibility of using a
recombinase-based lineage-tracing system for fate
mapping in the mouse.
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Results and discussion
The strategy [4] we used for fate mapping cells of the
mouse embryonic midbrain–hindbrain constriction involved
creating two types of transgenic mice and breeding them to
obtain double transgenics for analysis (Figure 1a). One line
(En2–cre mice) expresses Cre recombinase under the
control of an Engrailed-2 (En2) genomic regulatory fragment
[5,6] that directs expression to the embryonic
midbrain–hindbrain constriction region. Cre recombinase
from bacteriophage P1 catalyzes site-specific recombination
between loxP DNA sites [3] and this system has been
shown to be functional in transgenic mice [7,8]. The
second, ‘reporter’, line (cβ–STOP–lacZ) has a loxP–stop-of-
transcription/translation–loxP–lacZ (STOP–lacZ) cassette
[8] driven by regulatory sequences from the widely
expressed chick β-actin gene (Figure 1c and see Supple-
mentary material published with this paper on the internet).
On crossing heterozygous En2–cre and reporter mice, one
quarter of the progeny should consist of double transgenics.
Only cells that express Cre from the En2 regulatory ele-
ments should undergo recombination between the loxP
Figure 1
The Cre–loxP fate-mapping approach. (a) Schematic diagram showing
the fate-mapping strategy. See text for details. (b) The En2–cre
construct consists of a 2.5 kb En2 embryonic enhancer (thin black line)
and the En2 minimal promoter fragment (thick black line) which directs
expression of a cre cDNA with a metallothionein polyadenylation signal
(light gray box). (c) Schematic representation of the cβ–STOP–lacZ
construct. Dark gray numbered boxes, chicken β-actin exons; light blue
box, stop cassette; dark blue box, lacZ reporter gene; white box,
mouse protamine-1 (mPrm-1) 3′ UTR (untranslated region) and poly-
adenylation site; encircled arrows, loxP sequences.
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sites of the reporter construct, excising the STOP and per-
mitting lacZ expression. As the Cre-mediated excision is
cell heritable, the marked cells and all their progeny should
express lacZ at later stages even after cre is no longer
expressed. Thus, βgal staining in the brains of adult double-
transgenic animals should reveal the progeny of all cells that
expressed cre transiently during development.
The cβ–STOP–lacZ reporter mice were made by zygote
injection and random integration of the STOP–lacZ trans-
gene. Potential readthrough of lacZ expression in the
absence of Cre was examined by analyzing lacZ expres-
sion. Some cβ–STOP–lacZ mice exhibited scattered weak
blue staining in the hippocampus and less frequently in
the deep layers of the cortex adjacent to the corpus collo-
sum (Figure 2a) whereas no staining was observed in the
brains of control CD1 mice. As this nonspecific staining
was weak and not in the midbrain–hindbrain region, it was
not considered in the fate mapping.
As a positive control, reporter mice were mated with mice
transgenic for a human cytomegalovirus promoter driving
cre (CMV–cre) to determine the potential for lacZ expres-
sion. CMV–cre mice can express cre in all cells throughout
the two-cell to eight-cell stages (data not shown). There-
fore, double transgenics should reveal all possible sites of
lacZ expression in the reporter strain. Sagittal sections of
brains of double-transgenic adults revealed lacZ expres-
sion throughout the brain in the majority of specimens
(Figure 2b,c and see Supplementary material). The exact
pattern of lacZ expression, however, varied even within a
single litter. This variability most probably reflects the
multicopy nature of the reporter transgene array, which
permits a variety of recombination events that could result
in different levels of lacZ expression and/or regional
expression patterns. About 20% of double transgenics,
however, exhibited lacZ expression in all brain neurons
(Figure 2c). Construction of a reporter line containing a
single transgene would resolve this complication. We
attempted to create such a single-copy STOP–lacZ
reporter mouse using a ‘knock-in’ gene-targeting approach
[9] into exon 2 of the endogenous mouse β-actin gene (see
Supplementary material). However, this failed to produce
targeted animals that could express lacZ ubiquitously after
Cre-mediated excision of the STOP sequence (see Sup-
plementary material).
Adult CMV–cre;cβ–STOP–lacZ mice consistently showed
strong lacZ expression in the olfactory bulbs, cortex and
hippocampus. Expression in most midbrain and hindbrain
regions was also prominent, with the tectum (inferior and
superior colliculi) staining in 70%, the cerebellum in 80%,
and the anterior hindbrain in 75% of adults. The ventral
midbrain (tegmentum), however, expressed β-galactosi-
dase (βgal) in only 30% of double transgenics. These
results demonstrate that cβ–STOP–lacZ mice can be used
to map the fate of cells in all areas of the brain except the
tegmentum if three or more animals are analyzed and the
cumulative expression pattern of the animals is used. 
Embryonic day (E) 8.5 and 9.5 CMV–cre;cβ–STOP–lacZ
embryos exhibited at most only scattered lacZ-positive
cells across the head and in the myoblasts, heart and
somites (Figure 2d). By E14.5, however, embryos (n = 7)
expressed lacZ in a pattern suggesting that all post-mitotic
neurons can express lacZ (Figure 2e). Outside of the brain,
lacZ expression was detected in adults in the spinal cord,
dorsal root ganglia, sympathetic ganglia, heart and some
skeletal muscle, but not in other tissues (data not shown).
Our previous studies [5,6] have shown that a lacZ trans-
gene driven by a 2.5 kilobase (kb) En2 enhancer expresses
βgal activity specifically in the posterior half of the mid-
brain and cerebellar anlage at E9.5, although lacZ RNA
expression is much more restricted (D-L. Song and A.L.J.,
unpublished observations). βgal activity can be detected
between E8.5 and E12.5 with this transgene. A vector
666 Current Biology, Vol 8 No 11
Figure 2
The cβ–STOP–lacZ transgenic mice can express lacZ in post-mitotic
neurons throughout the brain. (a–c) Sagittal sections (2 mm) of
β-galactosidase-stained (blue) adult brains oriented with the forebrain
to left: (a) cβ–STOP–lacZ adult brains in the absence of Cre; (b,c)
lacZ expression in CMV–cre;cβ–STOP–lacZ adult double-transgenic
mice. (d) Embryonic day (E) 9.5 CMV–cre;cβ–STOP–lacZ double-
transgenic embryo (lateral view). (e) Sagittal bisection of an E14.5
double-transgenic head. Abbreviations: c, cortex; cer, cerebellum; ddi,
dorsal diencephalon; hind, hindbrain; hip, hippocampus; hyp,
hypothalamus; ic, inferior colliculus; sc, superior colliculus; teg,
tegmentum; vdi, ventral diencephalon; vtel, ventral telencephalon.
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expressing cre from the En2 enhancer was prepared and
used to make transgenic mice by zygote injection (see
Supplementary material). Fate-mapping experiments
were carried out with five different En2–cre transgenic
mouse lines. 
Whole-mount RNA in situ hybridization with a cre anti-
sense probe confirmed that all five En2–cre lines express
cre in a similar narrow dorsal domain in the midbrain–hind-
brain constriction at E9.5 (Figure 3a). Three lines (3,4,11)
were analyzed in more detail at E8.5 and E10.5. Cre
expression was never detected at E8.5 (5–10 somite stage;
data not shown). At E10.5, cre expression in each line was
weaker than at E9.5 and was detected in a more restricted
dorsal domain (Figure 3b and data not shown). Sagittal
section RNA in situ analysis with a cre probe did not detect
expression in the brains of E14.5 embryos from three
En2–cre lines (4,6,11), although a control En2 probe con-
firmed the integrity of the experiment.
To identify the group of cells derived from the cre-
expressing cells in En2–cre mice, each of the five En2–cre
transgenic lines was mated with cβ–STOP–lacZ mice and
the bisected heads of double-transgenic E14.5 embryos
stained for βgal (Figure 4). As cre is not detected in the
brain at E14.5 in our En2–cre transgenic mice, the specific
subset of midbrain and cerebellar neurons that express
lacZ represents the group of post-mitotic cells that derive
from the cre-expressing precursor cells present in the
dorsal midbrain–hindbrain constriction during E9–E12.
Expression of lacZ at E14.5 in En2–cre;cβ–STOP–lacZ
embryos was much more restricted than that seen in
control CMV–cre;cβ–STOP–lacZ double-transgenic
embryos (Figure 2e). Despite some variability in the
extent of staining between animals, lacZ expression was
observed in the cerebellum, tectum and ventral midbrain
of all En2–cre;cβ–STOP–lacZ embryos (Figure 4 and see
Supplementary material). Embryos derived from En2–cre
line 4 exhibited additional staining in the forebrain and,
from line 3, in the ventral diencephalon and hindbrain. As
this staining was not consistent among all the lines, it
probably reflects ectopic cre expression due to positional
effects at the sites of transgene insertion.
To determine the fate of cre-expressing cells in the dorsal
midbrain–hindbrain constriction, En2–cre;cβ–STOP–lacZ
F1 adult brains were examined. All five En2–cre lines
exhibited staining in the cerebellum, tectum and hip-
pocampus (Figure 4 and see Supplementary material).
Line 3 also exhibited lacZ expression in the hypothalamus
and hindbrain and line 4 in the telencephalon, which
probably reflects the ectopic lacZ expression seen in E14.5
embryos with these two En2–cre lines. Lines 3, 4 and 22
had scattered cells expressing lacZ in the tegmentum, as
did the double transgenics with all the En2–cre lines at
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Figure 3
The En2–cre transgene is expressed specifically in the embryonic dorsal
mid–hindbrain junction. Expression of cre was examined by whole-mount
RNA in situ hybridization with a cre antisense probe in (a) E9.5 (lateral
view) and (b) E10.5 (dorsal view) embryos from the En2–cre transgenic
lines indicated. Arrows identify regions of cre expression.
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Figure 4
Expression of lacZ in five En2–cre;cβ–STOP–lacZ double-transgenic
lines at E14.5 and in adults. Expression in the brain is restricted to the
cerebellum and dorsal midbrain. E14.5 brains are sagittally bisected
and adult brains are 2 mm midsagittal (midline) or lateral sections, as
indicated. βgal staining (blue) can be seen in the cerebellum, tectum
and ventral midbrain. The forebrain is to the left. Brain structures are as
identified in Figure 2.
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E14.5, indicating that this is a brain region derived from
embryonic cre-expressing cells.
βgal staining in the cerebellum of the five En2–cre lines in
double transgenics varied in its medio-lateral extent, with
all the lines expressing at the midline, with varying
degrees of mosaic expression laterally (Figure 4). In the
colliculi, lacZ expression was strongest in more medial and
posterior regions as well as having different rostral borders
in each En2–cre line. As the staining patterns were consis-
tent between animals carrying a particular En2–cre trans-
gene at both E14.5 and in the adult, the different staining
patterns in each transgenic line probably reflect slight dif-
ferences in cre expression due to position effects. In the
chick, granule cells are only derived from the hindbrain at
early somite stages, whereas Purkinje cells are derived
from the midbrain and cerebellum [10,11]. We therefore
analyzed sections of double transgenics from lines 6 and
11 (n = 4) to determine whether the spatial distribution of
both cell types was the same. In all medial to lateral sec-
tions analyzed, lacZ-expressing Purkinje and granule cells
were adjacent to each other, with no consistent areas
where one or the other cell type expressed lacZ alone. 
Our studies indicate that murine cells located in the dorsal
midbrain–hindbrain constriction during E9–E12 can pop-
ulate large regions of the murine colliculi and cerebellum.
The En2–cre lines involving smaller areas of the adult
brain marked cells in the medial region of the cerebellum
as well as cells scattered in the inferior colliculus, whereas
one of the En2–cre lines (line 3) marked the medial cere-
bellum and much of the lateral regions, as well as most of
the colliculi. A recent study of cell lineages in the mouse
cerebellum demonstrated that, as in chick, granule cells
are not clonally related to Purkinje cells, and that all large
clones populated the cerebellum along the entire antero-
posterior length and that different clones marked a medial
or a lateral domain of the cerebellum [12]. Our En2–cre
lines 6, 11 and 22 appear to mark a similar medial domain
of both Purkinje and granule cells. None of our lines
marks only a lateral domain, but line 3 marks both the
medial and lateral domains. In the clonal analysis, it was
not possible to determine when and where each initial cell
was marked, and so it is not feasible to derive a fate map
from such studies. Our fate-mapping analysis indicates
that the medial Purkinje cell clones observed in the
lineage study came from the midbrain–hindbrain 
constriction region.
Additional cre transgenic lines that further divide the mid-
brain and hindbrain regions, and a reporter line that is
expressed in the embryonic neuroepithelium, will enable a
more precise fate map to be established in mouse. The
approach demonstrated in the present study with the
cβ–STOP–lacZ transgenic reporter line can now be used to
build fate maps of other regions of the brain using different
promoters to drive the expression of cre in specific spatial
domains of the early embryonic brain. Fate maps of embry-
onic cells in other regions of the nervous system and in the
heart and skeletal muscles where this reporter transgene is
expressed could also be derived.
Supplementary material
A detailed Materials and methods section for the experiments
described here and detailed tables summarizing the transgenic expres-
sion patterns are published together with this paper on the internet.
Acknowledgements
We thank Margosia Kownaka and Anna Auerbach for technical assistance
with embryonic stem cell work, and C.C. Hui for providing lab space, advice
and support to D.L.Z. during some of these studies. We thank members of
the Joyner lab for their advice and suggestions, especially Sandrine Millet
for making comments on the manuscript. We thank Brian Sauer for gifts of
plasmids and advice, and Richard Behringer for mouse β-actin genomic
clones. D.L.Z. was supported by a NSERC of Canada Scholarship, an
Ontario Graduate Scholarship and an HSC RESTRACOM Studentship.
E.H.M. was supported by a Damon Runyan–Walter Winchell postdoctoral
fellowship. This work was funded by grants from the Canadian MRC,
NINDS and HFSP to A.L.J., and by NIH/NAIMS grant 1PO1 AR 42671 (to
P.I., B. Wold) to D.J.A.; A.L.J. and D.J.A. are investigators of the Howard
Hughes Medical Institute.
References
1. Joyner AL: Engrailed, Wnt and Pax genes regulate midbrain-
hindbrain development. Trends Genet 1996, 12:15-20.
2. Wassef M, Joyner AL: Early mesencephalon/metencephalon
patterning and development of the cerebellum. Persp Dev
Neurobiol 1997, 5:3-16.
3. Hoess RH, Abremski K: Interaction of the bacteriophage P1
recombinase Cre with the recombining site loxP. Proc Natl Acad
Sci USA 1984, 81:1026-1029.
4. O’Gorman S, Fox DT, Wahl GM: Recombinase-mediated gene
activation and site-specific integration in mammalian cells.
Science 1991, 251:1351-1355.
5. Logan C, Khoo WK, Cado D, Joyner AL: Two enhancer regions in
the mouse En-2 locus direct expression to the mid/hindbrain
region and mandibular myoblasts. Development 1993, 
117:905-916.
6. Song DL, Chalepakis G, Gruss P, Joyner AL: Two Pax-binding sites
are required for early embryonic brain expression of an
Engrailed-2 transgene. Development 1996, 122:627-635.
7. Orban PC, Chui D, Marth JD: Tissue- and site-specific DNA
recombination in transgenic mice. Proc Natl Acad Sci USA 1992,
89:6861-6865.
8. Lakso M, Sauer B, Mosinger B Jr, Lee EJ, Manning RW, Yu SH, et al.:
Targeted oncogene activation by site-specific recombination in
transgenic mice. Proc Natl Acad Sci USA 1992, 89:6232-6236.
9. Hanks M, Wurst W, Anson-Cartwright L, Auerbach AB, Joyner AL:
Rescue of the En-2 mutant phenotype by replacement of En-1
with En-2. Science 1995, 269:679-682.
10. Hallonet MER, Le Douarin NM: Tracing neuroepithelial cells in the
mesencephalic and metencephalic alar plates during cerebellar
ontogeny in quail-chick chimaeras. Eur J Neurosci 1993, 
5:1145-1155.
11. Alvarez Otero R, Sotelo C, Alvarado-Mallart RM: Chick/quail
chimeras with partial cerebellar grafts: an analysis of the origin
and migration of cerebellar cells. J Comp Neurol 1993, 
333:597-615.
12. Mathis L, Bonnerot C, Puelles L Nicolas J-F: Retrospective clonal
analysis of the cerebellum using genetic lacZ/lacZ mouse
mosaics. Development 1997, 124:4089-4104.
668 Current Biology, Vol 8 No 11
Fate mapping of the mouse midbrain–hindbrain constriction
using a site-specific recombination system 
Dawn L. Zinyk, Eric H. Mercer, Esther Harris, David J. Anderson 
and Alexandra L. Joyner
Current Biology 11 May 1998, 8:665–668
S1
Materials and methods
Construction of plasmids
The En2–cre transgene was constructed from the plasmids pB9 [S1],
pKS(Sal)2 (compliments of M. Hanks), pMC12 (compliments of D.L.
Song), and pBS185. The En2 minimal promoter [S2], obtained as a
2.3 kb BamHI–SmaI fragment from pB9, was fused with the 3.0 kb
BamHI–SmaI vector backbone from pKS(Sal)2. The En2 embryonic
enhancer [S2,S3] obtained as a 2.6 kb BamHI fragment from pMC12,
was inserted into the BamHI site upstream of the En2 promoter. The
construct was completed by inserting the cre coding region with a met-
allothionein polyadenylation signal, obtained as a blunted 2.4 kb
HindIII–XhoI fragment from pBS185, into the blunted ClaI site down-
stream of the En2 promoter.
The cβ–STOP–lacZ reporter transgene consists of the following ele-
ments, in 5′ to 3′ order: (1) a 3.1 kb fragment of the chick β-actin pro-
moter including the first exon, first intron, and the 5′ untranslated
portion of the second exon; (2) a loxP site; (3) a STOP sequence
[S4] containing an inverted his3 element with a false translational
stop, and an SV40 splice donor/poly(A)-addition site; (4) a second
loxP site; (5) the lacZ coding sequence containing a nuclear localiza-
tion signal (nlacZ); (6) the 3′ untranslated region (UTR) of the mouse
protamine-1 (mPrm-1) gene, included to improve expression of the
transgene. Briefly, this construct was generated by first cloning the
SalI/BglII fragment of the plasmid pnlacF into the SmaI site of plasmid
pBSlox2, thereby placing the nlacZ coding and mPrm-1 3′ UTR
sequences downstream of tandem loxP sites separated by a
polylinker region containing XhoI, BglII and HindIII sites, in an interme-
diate plasmid called pX2Z3 (E.M., unpublished). A 1.3 kb
BamHI–HindIII fragment containing the STOP sequence from
plasmid pBS241 [S4] was then inserted between the BglII and
HindIII sites flanked by the tandem loxP sites in pX2Z3, to generate
pXSTOPXnZ. Finally, a 3.1 kb SalI–XbaI fragment from the plasmid
pβact-1 containing the chick β-actin promoter was cloned between
SalI and XbaI sites located upstream of the 5′-most loxP sites in
pXSTOPXnZ, to generate the final plasmid pβact-XSTOPX-nlacZ
(referred to in this study as cβ–STOP–lacZ). Transgenic mice were
generated by injecting the 8.2 kb SalI–Asp718 fragment from this
plasmid into zygotes. A detailed restriction map of this plasmid is
available on request.
To generate the mouse (m) β–STOP–lacZ targeting vector to insert a
(loxP-STOP-loxP-nlacZ) reporter cassette into the second exon of the
mouse β-actin locus, the following steps were performed, in brief. A
3.9 kb SalI–XhoI fragment containing the 3′ arm of the mouse β-actin
gene was cloned into SmaI-digested pUC19, to generate pUC-Act3′-
2. In parallel, a fragment containing the bacterial neomycin-resistance
gene (neor) followed by the SV40 intron and three consecutive SV40
poly(A)-addition sites [S5] was inserted between the tandem loxP sites
in the plasmid pX2Z3, to generate the intermediate pXneoXnZ. The 3′
β-actin arm, with the EcoRV site inactivated, was then transferred from
pUC-Act3′ to a position immediately downstream of the lacZ coding
sequence, to generate pXneoXnZAc3′. A fragment containing the
PGK-tk cassette fused to the 5′ arm of the mouse β-actin gene (a
1.2 kb SalI–XbaI fragment with the initiator codon deleted) was ulti-
mately inserted upstream of the 5′-most loxP site to generate the final
targeting construct. The 5′ and 3′ arms of the mouse β-actin gene were
the generous gift of Richard Behringer.
Transgenic CMV–cre transgenic mice were generated from a linearized
fragment derived from plasmid pBS185 (the generous gift of Brian
Sauer), which contains the CMV promoter-enhancer, the cre coding
sequence, and introns and the 3′ UTR from the metallothionein-I (MT-I)
gene. The position of insertion and number of transgene inserts
(30–40) in line 32-3 does not appear to be deleterious, as homozy-
gous cβ–STOP–lacZ mice appear healthy.
Screening of transgenic mice
Transgenic mice were generated [S6] and identified by Southern blot
analysis. For En2–cre mice, tail DNA was digested with EcoRI and
probed with a 683 bp BamHI–MluI cre-containing fragment from
pBS185. For cβ–STOP–lacZ mice, tail DNA was digested with EcoRV
and probed with a 1.1 kb EcoRI–EcoRV nlacZ-containing fragment from
the original transgene vector. After founders were established, genotyp-
ing was usually done by three-primer PCR. Yolk sac or tail DNA from
En2–cre (0.18 µg) or cβ–STOP–lacZ (0.06 µg) was amplified for 27
cycles (1 min at 94°C, 1 min at 62°C, 1.5 min at 72°C) on a thermal
cycler. The 5′ cre primer was 5′-CATTTCGTGATGAATGCCAC-3′, the
5′ endogenous mouse metallothionein primer (which excludes
sequence in common with the mouse metallothionein polyadenylation
site downstream of cre) was 5′-CCGTAGCTCCAGCTTCACC-3′, and
the common 3′ MT primer was 5′-ACTTGCAGTTCTTGCAGGC-3′. The
5′ lacZ primer was 5′-GGTCGCTACCATTACCAGTTG-3′, the 5′
endogenous mouse protamine-1 primer (which excludes sequences in
common with the mouse protamine-1 polyadenylation site downstream
of lacZ) was 5′-AGGTGGTGTCCCCTGCTC-3′ and the common 3′
mouse protamine-1 primer was 5′-ACGCAGGAGTTTTGATGGAC-3′.
Half of the 20 µl reaction volume was analyzed on a 2% agarose gel.
With the En2/cre primers, the wild-type allele is indicated by a 588 bp
band, whereas the En2/cre transgene produces a 668 bp band. With
the cβ–STOP–lacZ primers, wild type has a 332 bp band, whereas the
cβ–STOP–lacZ transgene produces a 349 bp band.
Detection of β-galactosidase activity
E9.5 embryos were dissected into cold phosphate-buffered saline
(PBS) and transferred as dissected into PBS on ice. When all embryos
were dissected, they were changed into cold paraformaldehyde (PFA)
4%/PBS and rocked at 4°C for 1 h. After fixation, embryos were
washed three times for 30 min with wash buffer (2 mM MgCl2, 0.02%
Nonidet-P40, 0.1 M phosphate buffer pH 7.3) once at 4°C and twice at
room temperature. Embryos were then transferred to prewarmed X-gal
solution (0.1 mg/ml X-gal/DMF, 2.12 mg/ml potassium ferrocyanide
and 1.64 mg/ml potassium ferricyanide in wash buffer) and placed at
37°C overnight. The next day, they were washed twice with PBS then
placed in 10% formalin at 4°C overnight. Embryos were then washed
twice with PBS and stored in 70% ethanol at 4°C.
E14.5 embryos to be stained were dissected into cold PBS, their
heads pinched off with forceps as far down the shoulders as possible
without taking the arms, and transferred as dissected into 50 ml PBS
on ice (≤6 heads per tube). When all embryos were dissected, they
were changed into cold PFA 4%/PBS and allowed to rock at 4°C for
4 h. Following fixation, embryo heads were either cut sagittally at the
midline with a scalpel blade and washed in PBS or were transferred
into cold 30% sucrose/PBS and allowed to sit at 4°C overnight until
they sank. Such embryo heads were dried on lens paper and mounted
in OCT. A cryostat was used to cut sagittally to midline. Three to four
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head-containing blocks were placed in 50 ml tubes and allowed to rock
in 40 ml of wash buffer at room temperature for 15 min and then in
fresh 40 ml wash buffer for 30 min. Three to four brains, cut with a
scalpel or cryostat, were then put into 15–20 ml of prewarmed X-gal
solution and allowed to stand covered at 37°C overnight. After one
PBS rinse, heads were placed in 40 ml 10% formalin for 4 h to
overnight. Heads were then rinsed with PBS and stored in 70%
ethanol at 4°C.
Adult brains were dissected out dry, cooled at 4°C for 3 min and sliced
sagittally into 2 mm slices. The slices were transferred to room temper-
ature PFA 4%/PBS and then placed on ice until all brains were fin-
ished. The brain slices were changed into fresh cold PFA 4%/PBS and
placed at 4°C for 1 h: 15 min standing, 45 min rocking. After fixation,
brains were washed three times for 30 min with wash buffer, once at
4°C and twice at room temperature. They were then changed into pre-
warmed X-gal solution and placed at 37°C overnight. The next day,
brains were washed twice with PBS then placed in 10% formalin at
4°C overnight. Brains were then washed twice with PBS and stored in
70% ethanol at 4°C.
RNA in situ hybridization
Whole-mount RNA in situ procedures were carried out according to
Conlon and Rossant [S7].
Production of targeted mice: ES cell culture, screening for
homologous recombinants and chimera production
The mβ–STOP–lacZ targeting construct was generated by homolo-
gous recombination in embryonic stem (ES) cells of the
mβ–STOP–lacZ targeting construct into the second exon of the mouse
β-actin gene [S8]. The mβ–STOP–lacZ targeting construct was
released from the plasmid by SalI digestion and then introduced into
ES cells by electroporation. The R1 ES cell line [S9] was propagated,
electroporated and selected as described by Wurst and Joyner [S8].
After positive-negative selection with G418/ganciclovir-containing
media, surviving ES cell clones were analyzed by genomic Southern
blot analysis using two external probes, a 5′ 0.37 kb EcoRV fragment
and a 3′ 0.48 kb XhoI–BamHI fragment. Genomic DNA digested with
EcoRV and probed with the 5′ probe gave a 1.4 kb wild-type and
5.3 kb mutant fragment, and probed with the 3′ probe gave a 8.2 kb
wild-type and 12.5 kb mutant band. Southern blot analysis identified 3
of 55 neomycin- and ganciclovir-resistant clones as being correctly tar-
geted. Two of the targeted lines were used to produce chimeras
through aggregration with morulae [S10]. Three chimeras from one line
were found to transmit the embryonic stem cell genotype to heterozy-
gous mice after breeding with CD1 mice, referred to as β-actinneolacZ.
Homozygous β-actinneolacZ mice were never obtained, suggesting that
disruption of the β-actin gene results in embryonic lethality. Tail or yolk-
sac DNA (~10 µg) was digested with EcoRV and run on a 1% agarose
gel. A 370 bp EcoRV–XhoI β-actin-containing fragment of the original
targeting construct was used as the hybridization probe.
To determine the potential for lacZ expression from the β-actin locus, β-
actinneolacZ mice were mated with mice carrying a CMV–cre transgene,
a different line than the one used to study the STOP–lacZ mice. From
this cross, 4 of 11 progeny were identified as carrying both the tar-
geted β-actin allele and the CMVcre construct. Two of the double
transgenics carried the β-actinlacZ allele generated by Cre-mediated
deletion of neor in most cells. One of the β-actinlacZ females was
crossed with a CD1 male and killed when the embryos reached E11.5.
Various tissues were removed from the mother and half of each adult
tissue was used for either βgal staining or northern blot analysis with a
lacZ probe. As a control for lacZ expression, tissues from a mouse car-
rying the ROSA26 gene trap insertion that expresses lacZ ubiquitously
[S11] were also analyzed. Whereas every cell type in all ROSA tissues
analyzed expressed lacZ, only the brain of the adult β-actinlacZ mouse
showed any staining, primarily limited to the cortex, granular cells of the
cerebellum and hippocampus (data not shown). Northern blot analysis
did not detect a lacZ transcript in any of the β-actinlacZ tissues whereas
a transcript was detected in all of the ROSA26 tissues (data not
shown). The fact that a lacZ transcript was not detected in the brain
tissues of the β-actinlacZ mouse in spite of βgal activity probably reflects
the differing sensitivities of the two assays. Five of the nine E11.5
embryos recovered from the β-actinlacZ mouse carried the β-actinlacZ
allele and they exhibited only scattered βgal staining in cells in the heart
and, in one embryo, also in the spinal cord (data not shown). Similar
results were obtained with embryos from the other β-actinlacZ mouse.
Targeting elsewhere in the β-actin gene might produce more robust
lacZ expression, although at least one other attempt to produce a gene
trap in the first intron did not result in ubiquitous expression [S12].
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Supplementary material S3
Table S1
Percentage of animals expressing bgal in various regions of
CMV–cre;cβ–STOP–lacZ adult brains.
% βgal staining (n = 20)
Brain region + ± –
Olfactory bulbs 85 15 0
Cortex 70 30 0
Ventral telencephalon 40 30* 30
Hypothalamus 20 15† 65
Thalamus 65 35‡ 0
Hippocampus 85 5 10
Tectum 30 40§ 30
Tegmentum 25 5 70
Cerebellum 40 50¶ 10
Hindbrain 25 50II 25
+ denotes strong expression in most or all cells; ± denotes mosaic
staining; – denotes expression in no or very few cells. *Ventral
telencephalon staining is strongest in the striatum. †Only a small group
of cells express in the hypothalamus. ‡Thalamus stains most strongly
anteriorly. §Often layer-specific expression in the tectum. ¶Expression
in many animals was stronger in the posterior cerebellum. IIExpression
only in the pontine nucleus of the metencephalon.
Table S2
Percentage of animals with βgal staining in various brain regions of En2–cre;cβ–STOP–lacZ double-transgenic E14.5 embryos.
Line 3 Line 4 Line 6 Line 11 Line 22
(n = 8) (n = 8) (n = 4) (n = 8) (n = 3)
Brain region + ± – + ± – + ± – + ± – + ± –
Cortex 100 50 50 100 100 100
Ventral telencephalon 100 12 88 100 100 100
Dorsal diencephalon 100 12 88 100 100 100
Ventral diencephalon 100 12 88 100 100 100
Superior colliculus 100 100 50 50 62 38 100
Inferior colliculus 100 100 50 50 62 38 100
Tegmentum 100 50 50 50 50 12 88 100
Cerebellum 100 50 50 25 75 12 88 33 67
Metencephalon 100 62 38 25 75 100 100
+ denotes strong staining in most or all cells; ± denotes mosaic staining; – denotes no or few cells staining.
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Table S3
Percentage of animals with βgal staining in various brain regions of En2–cre;cβ–STOP–lacZ double-transgenic adults.
Brain region Line 3 Line 4 Line 6 Line 11 Line 22
(n = 4) (n = 3) (n = 5) (n = 4) (n = 4)
+ ± – + ± – + ± – + ± – + ± –
Cortex 100 67 33 100 100 100
Ventral telencephalon 100 100 100 100 100
Thalamus 100 100 100 100 100
Hypothalamus 50 50 100 100 100 100
Hippocampus 100* 100* 100* 100* 100*
Superior colliculus medial 75 25 100 20 80 100 50 50
lateral 75 25 33 67 100 100 100
Inferior colliculus medial 75 25 100 60 40 25 75 75 25
lateral 75 25 67 33 100 100 100
Tegmentum medial 100 33 67 20 80 100 50 50
lateral 100 33 67 100 100 100
Cerebellum medial 75 25 33 67† 100† 100† 100
lateral 100 100 40† 60 50 50 50 50
Hindbrain 100 100 100 100 100
+ denotes strong staining in most or all cells; ± denotes mosaic staining;
– denotes no or few cells staining. *Weak and variable staining was
observed in control reporter animals. †Expression was strongest in the
posterior cerebellum. Olfactory bulbs did not stain in all samples.
